Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Journey Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Journey Medical's regulatory disclosures and financial reporting.
Journey Medical Corp CFO Joseph Benesch reported significant equity compensation grants on June 17, 2025. The insider received two major awards:
- 28,907 Restricted Stock Units (RSUs) vesting in three equal annual installments from January 2026 to January 2028
- 41,860 Stock Options with a strike price of $6.31, vesting similarly over three years and expiring June 17, 2035
Following these transactions, Benesch now beneficially owns 232,464 shares directly, including various restricted stock units. These equity grants appear to be part of the company's executive compensation program under their 2015 Stock Plan. The awards' three-year vesting schedule suggests a long-term retention strategy for the CFO position.
Journey Medical Corp reported significant insider activity as President & CEO Claude Maraoui received new equity compensation awards on June 17, 2025. The transactions include:
- 49,277 restricted stock units granted at $0, vesting in three equal annual installments from January 2026 to January 2028
- 82,915 stock options granted with a strike price of $6.31, also vesting over three years from January 2026 to January 2028
Following these transactions, Maraoui beneficially owns 2,397,590 shares directly, including previously granted restricted stock units. As both a Director and CEO, this equity compensation aligns with long-term shareholder interests through a three-year vesting schedule. The grants were made under the company's 2015 Stock Plan, demonstrating continued executive retention efforts.